Tyme Technologies ROE 2024

Mit csinál Tyme Technologies?

Tyme Technologies Inc is a biopharmaceutical company specializing in the development of cancer drugs. The company was founded in 2011 by Steve Hoffman in New York City. Tyme Technologies Inc aims to provide a solution for the urgent need for new cancer drugs. The business model of Tyme Technologies Inc focuses on research and development of therapies for various types of cancer. The company takes an innovative approach by targeting the metabolism of tumor cells to combat them. The goal is to provide personalized medicine to cancer patients, tailored to their specific cancer types and with fewer side effects. Tyme Technologies has achieved success in various areas and is actively working on establishing cancer treatment products. The company engages in its own research as well as collaborations with other companies and institutions. One of Tyme Technologies' areas of focus is the research and development of drugs for triple-negative breast cancer. This type of cancer is known to be very aggressive and spreads quickly. Tyme Technologies has developed a promising drug called SM-88, which aims to disrupt the metabolic processes in cancer cells, causing them to die. Another significant project of Tyme Technologies is the research and development of drugs for glioma, a particularly aggressive brain tumor for which there are currently no effective therapies. The company has successfully tested the drug SM-88 in a phase II study for this purpose. Tyme Technologies has also focused on cancer treatment in children. The company has conducted clinical trials for the treatment of neuroblastoma and osteosarcoma, both of which are rare and particularly aggressive types of cancer that mainly affect children. In terms of product offerings, Tyme Technologies has introduced various products to the market. One of them is the NLC-001 immunotherapy program, which focuses on activating the body's immune response against cancer cells. The company has also developed a test procedure for personalizing therapy in patients with triple-negative breast cancer, based on the patient's genetic profile. In summary, Tyme Technologies Inc is an emerging biopharmaceutical company specializing in the development of personalized therapies to combat various types of cancer. With its innovative technology, the company has already achieved significant success, particularly in the development of drugs for triple-negative breast cancer and brain tumors. The company continuously collaborates with other companies and institutions and invests in research and development of new cancer drugs in the long term. Tyme Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.